文献速递细菌感染、耐药与抗菌药物

门诊尿路感染抗生素治疗对共栖肠杆菌科细菌耐药性的影响:一项多国前瞻性队列研究

Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study.
PubMed 文献 · Clin Microbiol Infect · 2018-01-10

该多国前瞻性队列研究于2011年1月至2013年8月在比利时、波兰和瑞士的基层医疗站点纳入300户家庭(205户暴露、95户非暴露)共716名参与者,评估门诊尿路感染抗生素使用对肠道定植的环丙沙星耐药肠杆菌科细菌(CIP-RE)和产超广谱β-内酰胺酶肠杆菌科细菌(ESBL-PE)的影响。结果显示氟喹诺酮治疗导致CIP-RE患病率在停药后28天出现两倍升高(aPR 2.0,95%CI 1.2-3.4),而呋喃妥因对CIP-RE无影响。

要点

  • 氟喹诺酮治疗使停药后28天CIP-RE患病率升高(aPR 2.0,95%CI 1.2-3.4),需伤害人数为12。
  • 呋喃妥因对CIP-RE(aPR 1.0,95%CI 0.5-1.8)或NIT-RE无影响。
  • 家庭内暴露于CIP-RE或ESBL-PE与个体定植风险增加相关(aPR分别为1.8和3.4)。

核心结论

  • 研究结果支持在基层医疗中避免将氟喹诺酮类作为尿路感染的一线治疗,并提示可能通过干预措施阻断耐药肠杆菌科细菌在家庭内的传播。

研究设计与样本

  • 前瞻性队列研究,2011年1月至2013年8月在比利时、波兰和瑞士的基层医疗站点开展。
  • 纳入因疑似尿路感染或无症状菌尿需要抗生素的门诊患者(暴露患者)、不需要抗生素的门诊患者(非暴露患者),以及每位患者的1至3名家庭接触者。
  • 共纳入300户家庭(205户暴露、95户非暴露),716名参与者。
  • 在基线(S1)、抗生素疗程结束时(S2)和S2后28天(S3)采集粪便样本检测CIP-RE、ESBL-PE、呋喃妥因耐药肠杆菌科细菌(NIT-RE)及任何肠杆菌科细菌。

主要发现

  • 暴露患者中大多数接受呋喃类(86例;42%)或氟喹诺酮类(76例;37%)治疗。
  • CIP-RE在202名(28%)参与者的16%(328/2033)样本中被检出。
  • 氟喹诺酮治疗导致肠杆菌科细菌在S2暂时抑制,随后在S3时CIP-RE患病率出现两倍升高(aPR 2.0,95%CI 1.2-3.4),需伤害人数为12。
  • 呋喃妥因对CIP-RE(aPR 1.0,95%CI 0.5-1.8)或NIT-RE无影响。
  • ESBL-PE在71名(10%)参与者的5%(107/2058)样本中被检出,定植与抗生素暴露无关。

临床怎么用

  • 作者认为,研究结果支持在基层医疗中避免将氟喹诺酮类作为尿路感染的一线治疗。
  • 作者建议,可考虑通过干预措施阻断耐药肠杆菌科细菌在家庭内的传播。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We quantified the impact of antibiotics prescribed in primary care for urinary tract infections (UTIs) on intestinal colonization by ciprofloxacin-resistant (CIP-RE) and extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE), while accounting for household clustering. METHODS: Prospective cohort study from January 2011 to August 2013 at primary care sites in Belgium, Poland and Switzerland. We recruited outpatients requiring antibiotics for suspected UTIs or asymptomatic bacteriuria (exposed patients), outpatients not requiring antibiotics (non-exposed patients), and one to three household contacts for each patient. Faecal samples were tested for CIP-RE, ESBL-PE, nitrofurantoin-resistant Enterobacteriaceae (NIT-RE) and any Enterobacteriaceae at baseline (S1), end of antibiotics (S2) and 28 days after S2 (S3). RESULTS: We included 300 households (205 exposed, 95 non-exposed) with 716 participants. Most exposed patients received nitrofurans (86; 42%) or fluoroquinolones (76; 37%). CIP-RE were identified in 16% (328/2033) of samples from 202 (28%) participants. Fluoroquinolone treatment caused transient suppression of Enterobacteriaceae (S2) and subsequent two-fold increase in CIP-RE prevalence at S3 (adjusted prevalence ratio (aPR) 2.0, 95% CI 1.2-3.4), with corresponding number-needed-to-harm of 12. Nitrofurans had no impact on CIP-RE (aPR 1.0, 95% CI 0.5-1.8) or NIT-RE. ESBL-PE were identified in 5% (107/2058) of samples from 71 (10%) participants, with colonization not associated with antibiotic exposure. Household exposure to CIP-RE or ESBL-PE was associated with increased individual risk of colonization: aPR 1.8 (95% CI 1.3-2.5) and 3.4 (95% CI 1.3-9.0), respectively. CONCLUSIONS: These findings support avoidance of fluoroquinolones for first-line UTI therapy in primary care, and suggest potential for interventions that interrupt household circulation of resistant Enterobacteriaceae.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Stewardson AJ, Vervoort J, Adriaenssens N, et al. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study. Clin Microbiol Infect. 2018. PMID: 29331548. doi:10.1016/j.cmi.2017.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。